Association of the Serum Vascular Endothelial Growth Factor Levels With Benign Prostate Hyperplasia and Prostate Malignancies

Sharif, Mohammad Reza; Shaabani, Amirreza; Mahmoudi, Hossein; Nikoueinejad, Hassan; Akbari, Hossein; Einollahi, Behzad

doi:10.5812/numonthly.14778

Cited by 9 publications

(6 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular endothelial growth factor (VEGF) promotes vasculogenesis and angiogenesis that enhance blood vessel growth in tissues and maintains blood supply to tissues. Overexpression of VEGF in cancer tissues was found associated with tumor growth and metastasis 5 . Therefore, a drug that is potent regulating expression of VEGF in cancer tissues is attracting more and more attention in the anti-cancer drug development.…”

Section: Introductionmentioning

confidence: 99%

The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line

Xie

Liu

et al. 2015

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

The effects of tanshinone IIA on the proliferation of the human non-small cell lung cancer cell line A549 and its possible mechanism on the VEGF/VEGFR signal pathway were investigated. The exploration of the interaction between tanshinone IIA and its target proteins provides a feasible platform for studying the anticancer mechanism of active components of herbs. The CCK-8 assay was used to evaluate the proliferative activity of A549 cells treated with tanshinone IIA (2.5−80 μmol/L) for 24, 48 and 72 h, respectively. Flow cytometry was used for the detection of cell apoptosis and cell cycle perturbation. VEGF and VEGFR2 expression were studied by Western blotting. The binding mode of tanshinone IIA within the crystal structure of the VEGFR2 protein was evaluated with molecular docking analysis by use of the CDOCKER algorithm in Discovery Studio 2.1. The CCK-8 results showed that tanshinone IIA can significantly inhibit A549 cell proliferation in a dose- and time-dependent manner. Flow cytometry results showed that the apoptosis rate of tested group was higher than the vehicle control, and tanshinone IIA-treated cells accumulated at the S phase, which was higher than the vehicle control. Furthermore, the expression of VEGF and VEGFR2 was decreased in Western blot. Finally, molecular docking analysis revealed that tanshinone IIA could be stably docked into the kinase domain of VEGFR2 protein with its unique modes to form H-bonds with Cys917 and π–π stacking interactions with Val848. In conclusion, tanshinone IIA may suppress A549 proliferation, induce apoptosis and cell cycle arrest at the S phase. This drug may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.

show abstract

Section: Introductionmentioning

confidence: 99%

The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line

Xie

Liu

et al. 2015

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…The PSA and VEGF concentrations detected by the multi-analyte sensing system in the sera of healthy controls (samples 1-3; 1.7-2.6 ng/mL for PSA and 66.8-90.4 pg/mL for VEGF) were lower than those of patients with PCa (samples 4-10; 8.5-13.1 ng/mL for PSA and 321.8-412.8 pg/mL for VEGF; Figure 6 A, B). Previous studies have shown that values above 4.0 ng/mL of PSA and 188.2 pg/mL of VEGF are considered abnormal 15 , 16 . No significant differences were observed in terms of PSA and VEGF levels measured by the multi-analyte sensing system compared with ELISA.…”

Section: Resultsmentioning

confidence: 99%

“…In patients with PCa, the prostatic gland contributes considerably to circulating VEGF-165 levels 14 . Previous studies have shown that VEGF-165 concentrations increase with increasing PSA levels in patients' serum and a VEGF-165 concentration above 188.2 pg/mL is considered abnormal 15 , 16 . Elevated plasma VEGF-165 levels could reflect prostatic VEGF-165 production, making VEGF-165 a potential tumor marker of PCa to increase the accuracy of PCa diagnosis with PSA detection.…”

Section: Introductionmentioning

confidence: 99%

Label-Free Biochips for Accurate Detection of Prostate Cancer in the Clinic: Dual Biomarkers and Circulating Tumor Cells

et al. 2017

View full text Add to dashboard Cite

Purpose: Early diagnosis of prostate cancer (PCa) is essential for the prevention of metastasis and for early treatment; therefore, we aimed to develop a simple, accurate, and multi-analyte assay system for early PCa diagnosis in this study. Experimental design: We fabricated three kinds of biochips then integrated into microfluidic device for simultaneous detection of vascularendothelial growth factor (VEGF), prostate-specific antigen (PSA), and PCa circulating tumor cells (CTC) in human serum for accurate diagnosis of PCa. Then the integrated device can be put in the ELISA reader for signal analysis after sample incubation, no necessary of further fluorescence staining or microscopy counting. Result: The integrated device has wide liner detection ranges (0.05-25 ng/mL for both PSA and VEGF, and 5-300 cells/mL for PCa CTC), as well as high levels of sensitivity and selectivity, and demonstrated a high correlation with an enzyme-linked immunosorbent assay for sample detection in patients. Also, the presented biochips could maintain their stability when stored at 37°C for 49 days without significant differences in the red-shift (<5%). Conclusions: We have successfully developed a multi-analyte sensing system for rapid and easy detection of PSA, VEGF, and PC3 cells in PCa samples using label-free glass-based chips. This method presents the advantages of a broad working range, high specificity, label-free, high-speed, stability, and low cost detection method for point-of-care testing of PCa.

show abstract

“…This discrepancy between the results is probably the effect of different composition and size of the studied groups. Applicability of serum VEGF has been confirmed in diagnosis of gastric [46], liver [47], colorectal [48], lung [49], prostate [50, 51], breast [20, 21, 52], ovarian cancer [27, 53, 54]. The literature data suggest that VEGF can be serum tumor marker in general regardless of its location, but additional analyzes are needed due to the ambiguity of results.…”

Section: Discussionmentioning

confidence: 99%

Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers

et al. 2019

View full text Add to dashboard Cite

Background The search of useful serum biomarkers for the early detection of cervical cancers has been of a high priority. The activation of Macrophage-Colony Stimulating Factor (M-CSF) and Vascular Endothelial Growth Factor (VEGF) is likely involved in the pathogenesis and spread of cancer. We compared the plasma levels of M-CSF and VEGF to the ones of commonly accepted tumor markers CA 125and SCC-Ag in three groups of patients: 1. the cervical cancer group (patients with either squamous cell carcinoma or adenocarcinoma); 2. the cervical dysplasia group; 3. the control group. Methods This cohort study included 100 patients with cervical cancer and 55 patients with cervical dysplasia. The control group consisted of 50 healthy volunteers. The plasma levels of VEGF and M-CSF were determined using ELISA, while CA 125 and SCC-Ag concentrations were obtained by the chemiluminescent microparticle immunoassay (CMIA). Results The median levels of M-CSF and VEGF as well as CA 125 and SCC-Ag in the entire group of cervical cancer patients, were significantly different compared to the healthy women group. In case of both the squamous cell carcinoma and the adenocarcinoma groups, plasma levels of M-CSF and VEGF were higher compared to the control group. No significant differences in the studied parameters between the squamous cell carcinoma and the adenocarcinoma group were observed. The highest sensitivity and specificity were obtained for VEGF (81.18 and 76.00%, respectively) and SCC-Ag (81.18%; 74.00%) in the squamous cell carcinoma group and for VEGF (86.67%; 76.00%) in the adenocarcinoma group. The area under the ROC curve for VEGF was the largest in the adenocarcinoma group followed by the squamous cell carcinoma group (0.9082 and 0.8566 respectively). Conclusions Obtained results indicate a possible clinical applicability and a high diagnostic power for the combination of MSC-F, VEGF, CA 125 and SCC-Ag in the diagnosis of both studied types of cervical cancer.

show abstract

Association of the Serum Vascular Endothelial Growth Factor Levels With Benign Prostate Hyperplasia and Prostate Malignancies

Cited by 9 publications

References 21 publications

The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line

The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line

Label-Free Biochips for Accurate Detection of Prostate Cancer in the Clinic: Dual Biomarkers and Circulating Tumor Cells

Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers

Contact Info

Product

Resources

About